Niemann-Pick Disease

Table of Contents

  1. Overview and Classification
  2. Types A and B: Sphingomyelinase Deficiency
  3. Type A: Classic Infantile Neuronopathic
  4. Type B: Chronic Non-Neuronopathic
  5. Niemann-Pick Type C: Cholesterol Trafficking Disorder
  6. NPC Clinical Presentation and Key Signs
  7. Cherry Red Spot and Ocular Findings
  8. Diagnosis: Enzyme Assay, Filipin, Oxysterols
  9. Treatment and Management
  10. Key Research Papers
  11. Featured Videos
  12. Connections

Overview and Classification

Niemann-Pick disease is a heterogeneous group of lysosomal storage disorders that share the common feature of sphingolipid or cholesterol accumulation within lysosomes of the body's cells. The disease was first described by Albert Niemann in 1914, who reported a severely ill infant with massive organomegaly and neurological deterioration. Ludwig Pick subsequently characterized the underlying lipid storage pathology in 1927, establishing the clinical and histological framework that bears their names.

Modern understanding recognizes Niemann-Pick disease as encompassing at least two distinct genetic entities with fundamentally different genes and biochemical mechanisms. Types A and B are caused by mutations in the SMPD1 gene, which encodes acid sphingomyelinase (ASM), resulting in sphingomyelin accumulation. Type C is caused by mutations in NPC1 or NPC2 genes, disrupting intracellular cholesterol trafficking rather than sphingomyelinase activity — making it a distinct disease that happens to share clinical overlap and historical naming with Types A and B.

The combined prevalence of all Niemann-Pick subtypes is approximately 1 in 120,000 to 1 in 150,000 live births. Types A and B occur most commonly in Ashkenazi Jewish populations due to founder mutations. Type C is pan-ethnic but is notably more common in the Nova Scotia Acadian population owing to a regional founder mutation. All subtypes are classified among the "neurovisceral" lysosomal storage diseases — disorders that affect both the nervous system and visceral organs — though the degree of neurological involvement varies considerably between subtypes. Early and accurate diagnosis is critical given the availability of disease-modifying therapy for Type B and substrate reduction therapy for Type C.

Back to Table of Contents

Types A and B: Sphingomyelinase Deficiency

Types A and B Niemann-Pick disease both result from mutations in the SMPD1 gene located on chromosome 11p15.4, which encodes acid sphingomyelinase (ASM), a lysosomal hydrolase. ASM normally cleaves phosphocholine from sphingomyelin, breaking it down within lysosomes. When ASM activity is severely deficient or absent, sphingomyelin cannot be catabolized and accumulates primarily within cells of the monocyte-macrophage system — liver (Kupffer cells), spleen, bone marrow, and lung alveolar macrophages — and in neurons in the case of the more severe Type A.

Sphingomyelin is a major structural phospholipid of cell membranes and myelin sheaths throughout the body. Its accumulation leads to the formation of characteristic foam cells — lipid-laden macrophages displaying a vacuolated, foamy cytoplasm on histological examination — which can be seen in liver, spleen, bone marrow aspirates, and bronchoalveolar lavage specimens. More than 180 distinct SMPD1 mutations have been catalogued. In Ashkenazi Jewish patients, three mutations — R496L, L302P, and fsP330 — account for the majority of Type A (severe, null-function) alleles, while Q292K and p.R476W are prevalent Type B (attenuated, residual-function) alleles.

The phenotypic severity correlates broadly with residual ASM enzyme activity: Type A patients typically retain less than 1% of normal ASM activity, while Type B patients retain approximately 5–10% residual activity. This residual activity is sufficient to prevent neuronal accumulation in most Type B patients, explaining the absence of significant neurological disease in that subtype. Genotype-phenotype correlation is strong at the extremes but intermediate mutations may produce overlapping presentations, sometimes described as an "intermediate" phenotype with mild neurological features and more severe visceral disease.

Back to Table of Contents

Type A: Classic Infantile Neuronopathic

Niemann-Pick Type A (NPA) represents the most severe form of acid sphingomyelinase deficiency, arising from severe SMPD1 mutations that abolish virtually all residual ASM activity (typically less than 1% of normal). NPA predominantly affects individuals of Ashkenazi Jewish descent, though it occurs in all ethnic groups. Affected infants typically appear normal at birth, with clinical onset between 3 and 6 months of age as sphingomyelin accumulates to pathological levels in multiple organ systems.

The hallmarks of NPA are massive hepatosplenomegaly, progressive neurodegeneration, and interstitial lung disease. The liver and spleen enlarge dramatically due to foam cell infiltration of the reticuloendothelial system, causing abdominal distension that is often the first clinical sign. Pulmonary involvement reflects accumulation of lipid-laden macrophages within the alveoli, producing bilateral diffuse infiltrates on chest radiography and progressive respiratory compromise.

Neurological deterioration is relentless: infants lose developmental milestones after a brief normal period, progress from hypotonia to spasticity and rigidity, develop severe feeding and swallowing dysfunction, and ultimately lose all voluntary motor activity. Fundoscopic examination reveals a cherry red spot at the macula in approximately 50% of NPA patients, reflecting ganglioside accumulation in retinal ganglion cells surrounding the fovea. Brain histology demonstrates ballooned neurons with vacuolated cytoplasm throughout the cerebral cortex, basal ganglia, and cerebellum, with widespread neuronal death. No effective treatment exists for the neurological component of NPA. Death typically occurs by 2 to 3 years of age from a combination of respiratory failure and neurological deterioration.

Back to Table of Contents

Type B: Chronic Non-Neuronopathic

Niemann-Pick Type B (NPB) results from SMPD1 mutations that permit 5–10% residual ASM activity, enough to prevent significant neuronal sphingomyelin accumulation while still producing substantial visceral disease. NPB is defined by its non-neuronopathic course — the absence of, or only minimal, primary central nervous system involvement — distinguishing it fundamentally from the devastating neurological picture of NPA. Age of onset ranges from early childhood to adulthood depending on mutation severity, and many patients are diagnosed incidentally through investigation of organomegaly or cytopenias.

Hepatosplenomegaly is the most consistent finding and may be massive, contributing to abdominal discomfort and restricted diaphragmatic excursion. Pulmonary disease is a major source of morbidity: lipid-laden macrophages infiltrate the alveolar spaces, producing bilateral diffuse interstitial infiltrates visible on chest CT and causing a restrictive pattern on pulmonary function testing. Progressive pulmonary compromise is a leading cause of morbidity and mortality in NPB. Cytopenias — thrombocytopenia, anemia, and leukopenia — result from hypersplenism combined with direct bone marrow infiltration by foam cells. Dyslipidemia is prominent: patients typically exhibit markedly low HDL cholesterol, elevated LDL, and elevated triglycerides, conferring substantially increased risk of premature atherosclerosis and cardiovascular disease.

Many NPB patients survive into their fourth to sixth decade, though pulmonary and hepatic complications worsen over time. A landmark advance arrived in 2022 when the FDA approved olipudase alfa (Xenpozyme, Sanofi) — a recombinant human acid sphingomyelinase — as the first enzyme replacement therapy (ERT) for ASM deficiency. In clinical trials, olipudase alfa significantly reduced spleen and liver volumes and improved lung diffusion capacity (DLCO) in adults with NPB, establishing it as the standard of care for patients with non-neuronopathic disease. Pediatric dosing is also approved.

Back to Table of Contents

Niemann-Pick Type C: Cholesterol Trafficking Disorder

Niemann-Pick Type C (NPC) is a genetically and biochemically distinct disease from Types A and B, despite sharing the historical Niemann-Pick designation. NPC is not a sphingomyelinase deficiency; rather, it is a disorder of intracellular cholesterol trafficking. Mutations in the NPC1 gene (chromosome 18q11.2), which account for approximately 95% of NPC cases, or the NPC2 gene (chromosome 14q24.3, ~5% of cases) impair the ability of cells to export unesterified free cholesterol from late endosomes and lysosomes.

The NPC1 protein is a large 13-transmembrane-domain glycoprotein located in the late endosomal/lysosomal membrane. Its NPC1 domain is structurally homologous to the sterol-sensing domains of SCAP and the Hedgehog receptor Patched, and it functions as a molecular pump that transfers unesterified cholesterol out of the lysosomal lumen to the endoplasmic reticulum and cell membrane for metabolic use. NPC2 is a small soluble luminal protein that binds cholesterol inside the lysosome and hands it to NPC1 for export. When either protein is dysfunctional, unesterified free cholesterol — along with sphingolipids including GM2 and GM3 gangliosides and glucosylceramide — becomes trapped within late endosomes and lysosomes.

In neurons, this trafficking defect is catastrophic: neurons cannot redistribute the cholesterol needed for normal membrane homeostasis and synaptic function, and the progressive lysosomal accumulation of cholesterol and gangliosides leads to neuronal dysfunction and death. The trapped cholesterol is critically unesterified — it cannot be stored as cholesterol esters — which is the basis for the diagnostic filipin staining test, which fluorescently labels free (unesterified) cholesterol and demonstrates its characteristic perinuclear lysosomal accumulation in patient fibroblasts under ultraviolet illumination.

Back to Table of Contents

NPC Clinical Presentation and Key Signs

NPC presents across a remarkably wide age range — from neonates to adults in their sixth decade — and the dominant clinical features differ substantially by age of onset. Neonatal presentations (5–10% of cases) manifest as cholestatic jaundice and hepatic failure resembling neonatal hepatitis syndrome. Although the liver disease may resolve spontaneously, approximately half of neonatal-onset patients die of hepatic failure before the neurological phase begins.

The classic childhood and adolescent presentation (onset ages 6–15), which is the most recognizable form, features four cardinal neurological findings. Vertical supranuclear gaze palsy (VSGP) is the hallmark sign: patients lose the ability to voluntarily move their eyes downward (and later horizontally) on command, while the oculocephalic (doll's-eye) reflex remains intact, confirming the supranuclear origin of the palsy. This dissociation between voluntary and reflex eye movement is highly characteristic and distinguishes NPC from internuclear ophthalmoplegia or myasthenia. Gelastic cataplexy — sudden bilateral loss of muscle tone triggered by laughter or strong emotion — is highly specific for NPC and not seen in Gaucher disease, Pompe disease, NPA, or NPB. Cerebellar ataxia produces a progressive broad-based gait, dysmetria, and dysarthria. Cognitive decline begins insidiously with learning difficulties and progresses to dementia. Dystonia and dysphagia emerge in later stages.

Adult-onset NPC (typically ages 15–60) frequently presents with psychiatric symptoms first — psychosis, depression, bipolar-like episodes, or personality change — leading to misdiagnosis as primary psychiatric illness. The mean diagnostic delay from first symptoms in adult-onset NPC exceeds 10 years. Neurological signs eventually emerge, including VSGP (often subtle initially), ataxia, and cognitive decline. Hepatosplenomegaly is variable: it is prominent in pediatric-onset NPC but may be absent or mild in adult-onset cases, which further complicates recognition. Early childhood onset (ages 2–6) typically begins with developmental delay and cerebellar ataxia as the first neurological features.

Back to Table of Contents

Cherry Red Spot and Ocular Findings

The cherry red spot is a distinctive macular finding on fundoscopic examination in which the fovea centralis appears as a bright red-orange circle surrounded by a grey-white halo of opacified retina. The underlying mechanism involves lysosomal accumulation of lipid or ganglioside material within the ganglion cell layer of the retina. These ganglion cells are densely packed throughout the macula but are completely absent at the fovea centralis. As they accumulate storage material, the ganglion cells become opaque and milky-white, obscuring the underlying choroidal vascular circulation except at the fovea, where the absence of ganglion cells allows the normal red-orange color of the choroidal blood supply to remain visible — producing the characteristic cherry red center against the pale surrounding retina.

The conditions most classically associated with cherry red spot are: (1) Tay-Sachs disease (GM2 gangliosidosis due to HEXA mutation) — the most classic and reliably present association; (2) Niemann-Pick Type A — present in approximately 50% of NPA cases, reflecting neuronal ganglioside co-accumulation alongside sphingomyelin; (3) GM1 gangliosidosis; (4) Metachromatic leukodystrophy (uncommon); and (5) central retinal artery occlusion — a vascular cause that is unilateral and acute rather than bilateral and progressive.

In NPC, cherry red spot is uncommon. The primary defect in NPC1/NPC2 is impaired cholesterol trafficking rather than a primary lysosomal gangliosidase deficiency, so although gangliosides (GM2, GM3) co-accumulate in NPC neurons to some degree, the level of retinal ganglion cell involvement is typically insufficient to produce a cherry red spot. The dominant ocular finding in NPC is instead the vertical supranuclear gaze palsy — an eye movement disorder of cortical-subcortical origin, not a retinal finding. This distinction is clinically important: in a patient with lysosomal storage disease, cherry red spot on fundoscopy points toward NPA or Tay-Sachs, while vertical downward gaze palsy with intact oculocephalic reflex points strongly toward NPC.

Back to Table of Contents

Diagnosis: Enzyme Assay, Filipin, Oxysterols

Accurate diagnosis requires distinguishing NPA/NPB from NPC because they are different genetic diseases requiring different workup strategies and have different treatments. The diagnostic approach is tailored to the suspected subtype based on clinical features and ethnicity.

For NPA and NPB, the primary diagnostic test is measurement of acid sphingomyelinase (ASM) enzyme activity in peripheral blood leukocytes or cultured skin fibroblasts. Activity below 10% of normal confirms the diagnosis. SMPD1 gene sequencing identifies the specific mutations, establishes carrier status for family members, and provides prognostic guidance. Bone marrow biopsy, while not required for diagnosis, demonstrates characteristic foam cells and sea-blue histiocytes — macrophages laden with lipofuscin and sphingomyelin that stain blue-green with Giemsa — a finding also seen in NPC bone marrow.

For NPC, the gold standard has historically been the filipin staining test: cultured skin fibroblasts derived from a skin punch biopsy are incubated with filipin, a fluorescent polyene antibiotic that specifically binds unesterified (free) cholesterol. Under UV fluorescence microscopy, NPC fibroblasts show intense perinuclear fluorescence reflecting massive lysosomal accumulation of free cholesterol, contrasting with the diffuse low-level pattern in normal cells. Classic NPC1 mutations produce a strongly positive filipin pattern (~80% sensitivity), while ~15% of cases — often missense mutations retaining partial protein function — show a weaker "variant" pattern requiring confirmatory sequencing.

Plasma oxysterols — particularly 7-ketocholesterol (7-KC) and 24(S),25-epoxycholesterol — are now the preferred first-line non-invasive screening test for NPC. These oxysterols are markedly elevated in NPC plasma, are highly sensitive and specific, and can be measured from a routine blood draw without the delay of fibroblast culture. NPC1 and NPC2 gene sequencing confirms the diagnosis and identifies the causative mutations. Brain MRI in advanced NPC shows white matter signal changes and progressive cerebellar atrophy.

Back to Table of Contents

Treatment and Management

Treatment strategies differ fundamentally between NPA/NPB (acid sphingomyelinase deficiency) and NPC (cholesterol trafficking disorder).

For Niemann-Pick Type B, olipudase alfa (Xenpozyme, Sanofi) — approved by the FDA in August 2022 — is the first and only disease-modifying treatment. It is a recombinant human acid sphingomyelinase administered by intravenous infusion, initially at low doses that are slowly escalated to avoid a hepatic acute-phase response from rapid sphingomyelin catabolism. Pivotal trial data demonstrated significant reductions in spleen volume (median ~47%), liver volume, and improvements in lung diffusion capacity (DLCO) in adults with NPB; pediatric approval followed. Infusion-related reactions are managed with premedication. Olipudase alfa does not address neurological disease and is not indicated for NPA, where progressive neurological damage makes visceral treatment palliative in context. For NPA, no effective neurologically targeted treatment exists; management is entirely supportive including nutritional support (gastrostomy feeding), respiratory management, and comfort-focused care.

For Niemann-Pick Type C, miglustat (Zavesca, Actelion) is the primary disease-modifying option. Miglustat is an iminosugar that inhibits glucosylceramide synthase, reducing glycosphingolipid synthesis and thereby decreasing the amount of glycolipid substrate that accumulates in lysosomes — a strategy known as substrate reduction therapy (SRT). It is approved for neurological manifestations of NPC in the European Union and many other countries, though not by the FDA specifically for NPC. Clinical trials and long-term observational data demonstrate that miglustat stabilizes or delays progression of the supranuclear gaze palsy, cerebellar ataxia, and swallowing dysfunction; it does not reverse established neurological damage, making early treatment initiation critical. Side effects include gastrointestinal disturbance (diarrhea, flatulence), tremor, and peripheral neuropathy requiring monitoring.

Arimoclomol, an amplifier of heat shock protein responses (HSP70 co-induction) that promotes correct folding of misfolded NPC1 protein, showed promise in early trials but failed to meet its primary endpoint in the Phase 3 COSETTE trial (2022); regulatory discussions are ongoing. Intrathecal 2-hydroxypropyl-beta-cyclodextrin (HPbCD), which mobilizes cholesterol from lysosomes, showed neurological stabilization in a natural history-controlled study and remains under active investigation. Gene therapy approaches targeting both NPC1 and SMPD1 are in preclinical and early clinical development. All subtypes benefit from supportive care: anti-epileptic drugs for seizures, physical and occupational therapy, dysphagia management (modified-texture diets, feeding tubes), and psychiatric pharmacotherapy for behavioral symptoms in adult-onset NPC.

Back to Table of Contents

Key Research Papers

  1. Patterson MC, et al. Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study. Lancet Neurol. 2007;6(9):765-772. PMID: 17689147
  2. Vanier MT. Niemann-Pick disease type C. Orphanet J Rare Dis. 2010;5:16. PMID: 20525256
  3. Schuchman EH, Desnick RJ. Types A and B Niemann-Pick disease. Mol Genet Metab. 2017;120(1-2):27-33. PMID: 27993478
  4. Geberhiwot T, et al. Consensus clinical management guidelines for Niemann-Pick disease type C. Orphanet J Rare Dis. 2018;13(1):50. PMID: 29625568
  5. Wraith JE, et al. Miglustat in adult and juvenile patients with Niemann-Pick disease type C: long-term data from a clinical trial. Mol Genet Metab. 2010;99(4):351-357. PMID: 20045668
  6. Pineda M, et al. Miglustat in patients with Niemann-Pick disease Type C (NPC): a multicenter observational retrospective cohort study. Mol Genet Metab. 2010;98(3):243-249. PMID: 19896883
  7. Ottinger EA, et al. Collaborative development of 2-hydroxypropyl-beta-cyclodextrin for the treatment of Niemann-Pick type C1 disease. Curr Top Med Chem. 2014;14(3):330-339. PMID: 24351160
  8. Ory DS, et al. Intrathecal 2-hydroxypropyl-beta-cyclodextrin decreases neurological disease progression in Niemann-Pick disease, type C1. J Clin Invest. 2017;127(4):1663-1674. PMID: 28248202
  9. Wasserstein MP, et al. The natural history of type B Niemann-Pick disease: results from a 10-year longitudinal study. Pediatrics. 2004;114(6):e672-7. PMID: 15574620
  10. Walkley SU, Suzuki K. Consequences of NPC1 and NPC2 loss of function in mammalian neurons. Biochim Biophys Acta. 2004;1685(1-3):48-62. PMID: 15465449
  11. Naureckiene S, et al. Identification of HE1 as the second gene of Niemann-Pick C disease. Science. 2000;290(5500):2298-2301. PMID: 11125141
  12. Carstea ED, et al. Niemann-Pick C1 disease gene: homology to mediators of cholesterol homeostasis. Science. 1997;277(5323):228-231. PMID: 9211849

Connections